Parametric Portfolio Associates LLC Acquires 7,727 Shares of DexCom, Inc. (NASDAQ:DXCM)

Share on StockTwits

Parametric Portfolio Associates LLC grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 187,504 shares of the medical device company’s stock after purchasing an additional 7,727 shares during the quarter. Parametric Portfolio Associates LLC owned about 0.20% of DexCom worth $27,983,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. raised its position in shares of DexCom by 1.5% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 4,643 shares of the medical device company’s stock valued at $696,000 after purchasing an additional 67 shares during the period. Steward Partners Investment Advisory LLC grew its stake in DexCom by 33.3% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 280 shares of the medical device company’s stock valued at $41,000 after buying an additional 70 shares during the last quarter. SeaCrest Wealth Management LLC grew its stake in DexCom by 5.4% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 1,413 shares of the medical device company’s stock valued at $211,000 after buying an additional 73 shares during the last quarter. First Republic Investment Management Inc. raised its holdings in DexCom by 3.3% in the 2nd quarter. First Republic Investment Management Inc. now owns 3,093 shares of the medical device company’s stock worth $463,000 after acquiring an additional 100 shares during the period. Finally, Wedbush Securities Inc. lifted its position in DexCom by 4.4% during the 2nd quarter. Wedbush Securities Inc. now owns 3,108 shares of the medical device company’s stock worth $466,000 after acquiring an additional 130 shares during the last quarter. 98.20% of the stock is owned by institutional investors and hedge funds.

In other news, Director Nicholas Augustinos sold 1,208 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $145.49, for a total value of $175,751.92. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Jeffrey Moy sold 4,601 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $149.85, for a total transaction of $689,459.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,459 shares of company stock worth $11,852,977. 0.88% of the stock is owned by company insiders.

DXCM has been the topic of several research analyst reports. Raymond James raised their price target on DexCom from $172.00 to $189.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Oppenheimer boosted their price objective on DexCom from $180.00 to $205.00 in a research report on Thursday, November 7th. BMO Capital Markets increased their target price on DexCom from $180.00 to $190.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of DexCom in a report on Monday, November 18th. Finally, Canaccord Genuity upped their price target on DexCom from $185.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $184.33.

Shares of NASDAQ DXCM opened at $228.66 on Wednesday. The firm has a market capitalization of $20.81 billion, a price-to-earnings ratio of 762.20 and a beta of 0.76. DexCom, Inc. has a one year low of $105.05 and a one year high of $229.76. The business has a fifty day simple moving average of $185.85 and a 200 day simple moving average of $157.93. The company has a current ratio of 5.63, a quick ratio of 5.26 and a debt-to-equity ratio of 1.41.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.45. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The firm had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. During the same quarter in the previous year, the firm posted $0.17 EPS. The business’s revenue for the quarter was up 48.6% on a year-over-year basis. On average, research analysts anticipate that DexCom, Inc. will post 1.41 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What is the definition of market timing?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.